<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               <BR>                  5     WARNINGS AND PRECAUTIONS<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                           Myelosuppression: Associated with neutropenia, thrombocytopenia and anemia. CBC should be done every 2 weeks for the first 2 months, then monthly. Reversible by withholding dose. Dose reduction may be required. (5.1)<BR><BR>                           <BR>                           QT Prolongation: Tasigna prolongs the QT interval. Correct hypokalemia or hypomagnesemia prior to administration and monitor periodically. (5.2) Avoid drugs known to prolong the QT interval and strong CYP3A4 inhibitors. (5.7)  Use with caution in patients with hepatic impairment (5.9). Obtain ECGs at baseline, seven days after initiation, and periodically thereafter, as well as following any dose adjustments. (5.2, 5.3, 5.6, 5.13)<BR><BR>                           <BR>                           Sudden deaths: Sudden deaths have been reported in patients with resistant or intolerant Ph+ CML receiving nilotinib. Ventricular repolarization abnormalities may have contributed to their occurrence. <BR><BR>                           <BR>                           Elevated serum lipase: Check serum lipase periodically. In case lipase elevations are accompanied by abdominal symptoms, interrupt doses and consider appropriate diagnostics to exclude pancreatitis. Caution is recommended in patients with history of pancreatitis. (5.4) <BR><BR>                           <BR>                           Liver function abnormality: Tasigna may result in elevations in bilirubin, AST/ALT, and alkaline phosphatase. Check hepatic function tests periodically. (5.5) <BR><BR>                           <BR>                           Electrolyte abnormalities: Tasigna can cause hypophosphatemia, hypokalemia, hyperkalemia, hypocalcemia, and hyponatremia. Correct electrolyte abnormalities prior to initiating Tasigna and monitor periodically during therapy. (5.6, 5.13)<BR><BR>                           <BR>                           Hepatic impairment: Nilotinib exposure is increased in patients with impaired hepatic function (at baseline). A dose reduction is recommended in these patients and QT interval should be monitored closely. (5.9)<BR><BR>                           <BR>                           Tumor Lysis Syndrome: Cases of tumor lysis syndrome have been reported in Tasigna treated patients with resistant or intolerant CML. Due to potential for tumor lysis syndrome, maintain adequate hydration and correct uric acid levels prior to initiating therapy with Tasigna. (5.10)<BR><BR>                           <BR>                           Drug interactions: Avoid concomitant use of strong inhibitors or inducers of CYP3A4. If patients must be co-administered a strong CYP3A4 inhibitor, dose reduction should be considered and the QT interval should be monitored closely. (5.7) <BR><BR>                           <BR>                           Food Effects: Food increases blood levels of Tasigna. <BR><BR>                           <BR>                           Avoid food 2 hours before and 1 hour after a dose. (5.8)<BR><BR>                           <BR>                           Total gastrectomy: More frequent follow-up of these patients should be considered. If necessary, dose increase may be considered (5.11). <BR><BR>                           <BR>                           Pregnancy: Fetal harm can occur when administered to a pregnant woman. Women should be advised not to become pregnant when taking Tasigna. (5.14, 8.1)<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     5.1     Myelosuppression<BR>                     <BR>                        Treatment with Tasigna can cause Grade 3/4 thrombocytopenia, neutropenia and anemia. Perform complete blood counts every two weeks for the first 2 months and then monthly thereafter, or as clinically indicated. Myelosuppression was generally reversible and usually managed by withholding Tasigna temporarily or dose reduction [<BR>                           s<BR>                           ee Dosage and Administration (<BR>                           2<BR>                           .2<BR>                           )]<BR>                           .<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     5.2     QT Prolongation<BR>                     <BR>                        Tasigna has been shown to prolong cardiac ventricular repolarization as measured by the QT interval on the surface ECG in a concentration-dependent manner [<BR>                           s<BR>                           ee <BR>                           Adverse Reactions (6.1), <BR>                           Clinical Pharmacology<BR>                            <BR>                           (12.4)]. Prolongation of the QT interval can result in a type of ventricular tachycardia called torsade de pointes, which may result in syncope, seizure, and/or death. ECGs should be performed at baseline, seven days after initiation, periodically as clinically indicated and following dose adjustments [see Warnings and Precautions (5.13)].<BR>                        <BR>                        Tasigna should not be used in patients who have hypokalemia, hypomagnesemia or long QT syndrome. Hypokalemia or hypomagnesemia must be corrected prior to initiating Tasigna and these electrolytes should be monitored periodically during therapy [see Warnings and Precautions (5.13)].<BR>                        <BR>                        Significant prolongation of the QT interval may occur when Tasigna is inappropriately taken with food and/or strong CYP3A4 inhibitors and/or medicinal products with a known potential to prolong QT. Therefore, co-administration with food must be avoided and concomitant use with strong CYP3A4 inhibitors and/or medicinal products with a known potential to prolong QT should be avoided [<BR>                           s<BR>                           ee <BR>                           Warnings and Precautions<BR>                            (5.7<BR>                           , 5.8<BR>                           )]. The presence of hypokalemia and hypomagnesemia may further enhance this effect [<BR>                           s<BR>                           ee <BR>                           Warnings and Precautions (<BR>                           5.6<BR>                           ,<BR>                            5.1<BR>                           3<BR>                           )].<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     5.3     Sudden Deaths<BR>                     <BR>                        Sudden deaths have been reported in patients with CML treated with nilotinib in clinical studies (n= 5,661; 0.3%). The relative early occurrence of some of these deaths relative to the initiation of nilotinib suggests the possibility that ventricular repolarization abnormalities may have contributed to their occurrence. <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     5.4     Elevated Serum Lipase<BR>                     <BR>                        The use of Tasigna can cause increases in serum lipase. Caution is recommended in patients with a previous history of pancreatitis. If lipase elevations are accompanied by abdominal symptoms, interrupt dosing and consider appropriate diagnostics to exclude pancreatitis. Test serum lipase levels monthly or as clinically indicated.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     5.5     Hepatotoxicity<BR>                     <BR>                        The use of Tasigna may result in elevations in bilirubin, AST/ALT, and alkaline phosphatase. Hepatic function tests should be checked monthly or as clinically indicated [see Warnings and Precautions (5.13)].<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     5.6     Electrolyte Abnormalities<BR>                     <BR>                        The use of Tasigna can cause hypophosphatemia, hypokalemia, hyperkalemia, hypocalcemia, and hyponatremia. Electrolyte abnormalities must be corrected prior to initiating Tasigna and these electrolytes should be monitored periodically during therapy [see Warnings and Precautions (5.13<BR>                           )<BR>                           ].<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     5.7     Drug Interactions<BR>                     <BR>                        The administration of Tasigna with agents that are strong CYP3A4 inhibitors or anti-arrhythmic drugs (including, but not limited to amiodarone, disopyramide, procainamide, quinidine and sotalol) and other drugs that may prolong QT interval (including, but not limited to chloroquine, clarithromycin, haloperidol, methadone, moxifloxacin and pimozide) should be avoided. Should treatment with any of these agents be required, it is recommended that therapy with Tasigna be interrupted. If interruption of treatment with Tasigna is not possible, patients who require treatment with a drug that prolongs QT or strongly inhibits CYP3A4 should be closely monitored for prolongation of the QT interval [<BR>                           s<BR>                           ee<BR>                            <BR>                           Boxed Warning, <BR>                           Dos<BR>                           age and Administration<BR>                            (2<BR>                           .2<BR>                           ),<BR>                            Drug Interactions<BR>                            (7.<BR>                           2<BR>                           )]<BR>                           .<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     5.8     Food Effects<BR>                     <BR>                        The bioavailability of nilotinib is increased with food. Tasigna must not be taken with food. No food should be taken for at least 2 hours before and for at least one hour after the dose is taken. Grapefruit products and other foods that are known to inhibit CYP3A4 should be avoided [<BR>                           s<BR>                           ee Boxed Warning, Drug Interactions (7.<BR>                           2<BR>                           ) and <BR>                           Clinical Pharmacology <BR>                           (12.3)].<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     5.9     Hepatic Impairment<BR>                     <BR>                        Nilotinib exposure is increased in patients with impaired hepatic function. A lower starting dose is recommended for patients with mild to severe hepatic impairment (at baseline) and QT interval should be monitored closely [see Dosage and Administration (2.2) and Use in Specific Populations (8.7)].<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     5.10     Tumor Lysis Syndrome<BR>                     <BR>                        Cases of tumor lysis syndrome have been reported in Tasigna treated patients with resistant or intolerant CML. Malignant disease progression, high WBC counts and/or dehydration were present in the majority of these cases. Due to potential for tumor lysis syndrome, maintain adequate hydration and correct uric acid levels prior to initiating therapy with Tasigna.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     5.11     Total Gastrectomy<BR>                     <BR>                        The exposure of nilotinib is reduced in patients with total gastrectomy. More frequent follow-up of these patients should be considered. Dose increase or alternative therapy may be considered in patients with total gastrectomy [<BR>                           see Clinical Pharmacology 12.3)].<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     5.12     Lactose<BR>                     <BR>                        Since the capsules contain lactose, Tasigna is not recommended for patients with rare hereditary problems of galactose intolerance, severe lactase deficiency with a severe degree of intolerance to lactose-containing products or of glucose-galactose malabsorption.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     5.13     Monitoring Laboratory Tests<BR>                     <BR>                        Complete blood counts should be performed every two weeks for the first two months and then monthly thereafter. Chemistry panels, including the lipid profile, should be checked periodically. ECGs should be obtained at baseline, seven days after initiation and periodically thereafter, as well as following dose adjustments [<BR>                           s<BR>                           ee Warnings and Precautions (5.2)]<BR>                           . Laboratory monitoring for patients receiving Tasigna may need to be performed more or less frequently at the physician’s discretion.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     5.14     Use in Pregnancy<BR>                     <BR>                        There are no adequate and well controlled studies of Tasigna in pregnant women. However, Tasigna may cause fetal harm when administered to a pregnant woman. Nilotinib caused embryo-fetal toxicities in animals at maternal exposures that were lower than the expected human exposure at the recommended doses of nilotinib. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of child-bearing potential should avoid becoming pregnant while taking Tasigna [see Use in Specific Populations (8.1)].<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>